AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2019
Mar 18, 2019
34564_dirs_2019-03-18_5ca07bc3-7e2e-4db9-a655-eed92ce910db.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2019-03-07
Reporting Person: Votruba Michal (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-03-07 | Stock Options (Right to Buy) | $7.91 | D | 10000 | Disposed | 2029-03-07 | Common Stock (10000) | Direct |
Footnotes
F1: The shares underlying this stock option vest as follows: one-third on each of 3/7/2020, 3/7/2021 and 3/7/2022, subject to the Reporting Person's continuous service to the Issuer through such dates.
F2: The Reporting Person immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. ("RSJ") pursuant to the policies of RSJ regarding stock ownership by its employees, as documented by an Agreement between the Reporting Person and RSJ. The Reporting Person is serving on the Board of the Issuer with the permission of RSJ.